Clinical Trials
28 trialsREVIVE
Asan Medical Center
MK-4280A-007
Merck Sharp & Dohme LLC
REGINA
Jules Bordet Institute
PARERE
Gruppo Oncologico del Nord-Ovest
A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
Bayer
TAPUR
American Society of Clinical Oncology
GBM AGILE
Global Coalition for Adaptive Research
MIRAGE
Istituto Oncologico Veneto IRCCS
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors
West China Hospital
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
Sun Yat-sen University
CodeBreak300
Amgen
MegaMOST
Centre Leon Berard
GISTAR-1
Ningbo Newbay Technology Development Co., Ltd
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
RELEVANT-HCC
Asan Medical Center
RECOMEND
Asan Medical Center
Regbone
Institute of Mother and Child, Warsaw, Poland
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
EREMISS
Centre Oscar Lambret
REGO-SARC
Centre Oscar Lambret
BREGO
Institut du Cancer de Montpellier - Val d'Aurelle
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
REPLACE
Translational Research in Oncology
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
DREAM
First Affiliated Hospital, Sun Yat-Sen University
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center